Keeping you updated

Our Services

Join our Webinar – NSCLC ALK & EGFR Insights with LENS

Conducting a comprehensive SLR in advanced-NSCLC is an incredibly resource intensive and challenging process, right?

  • You may be interested in ALK, EGFR and other NSCLC mutations?
  • You might need to assess clinical effectiveness (survival, response rate, safety) between targeted therapies such as brigatinib, alectinib, crizotinib, ceritinib, lorlatinib, afatinib, erlotinib and their impact based on key patient characteristics (age, mutation-subtype etc)?

We all look for real insights which are easily and readily accessible and configurable. But in reality, most SLRs are unwieldy and difficult to ‘fine-tune’ the research question.                                                

That's why on Thursday 21st September you should join our 30 minute webinar on Syndicated NSCLC SLR – LENS Landscape to find out more about:

  • NICE compliant NSCLC SLR methodology through a clear and pragmatic protocol
  • Role of SLR analytic application – LENS Landscape with insights from NSCLC

(even if you can't make it, register anyway so we can send you the slides and recording)

Title: From NSCLC SLR to Greater ALK & EGFR Insights with LENS
Date: Thursday 21st September 2017
Time: 1.00pm UK
Duration: 30 minutes including Q&A

To register, leave your details here. We look forward to you joining us!


Say Hola! to Curo at ESMO 2017

ESMO2017 banner

Are you Interested in different outcomes for EGFR or ALK therapies in NSCLC​?

Want to gain a deeper insight into the evidence for NSCLC EGFR and ALK therapies? Do you need to examine data between 1st, 2nd and 3rd generation ALKs or 1st, 2nd and 3rd generation EGFRS to get the bigger picture?

Come and see us at ESMO to get a deeper insight in to our syndicated LENS as well as an overview of our range of HEOR evidence and insights management solutions in oncology.

LENS Landscape NSCLC is a world class, pre-built SLR, focussing on EGFR and ALK driver mutations built using Curo's own LENS technology. It allows you to assess performance of major therapies, get instant insights and understand the impact of key effect modifiers by comparing data across a range of key endpoints.

Now part of The Envision Pharma Group, makers of the industry standard publications platform DataVision, Curo are established market leaders in delivering technology led solutions as well as value strategy in solid tumours and haem-oncology.

Contact us to say Hola! and arrange a meeting at ESMO or to schedule a demo of our tools.

CUR_ESMO17_web post_1.png

Curo welcomes Health Economics students Abi and Alicia

Curo are very pleased to welcome Alicia (pictured left) and Abi from the University of York, who will be joining us for the summer as part of their MSc Health Economics course.

In addition to completing dissertation projects, they’ll be learning about our unique position in the industry and utilising our tools to further their knowledge of gathering research evidence, reviewing literature and economic modelling.

Alicia studied Biotechnology (BSc. First Class Hons) at Cardiff University and became interested in our field through contact with Health Economists while on a placement with a life sciences recruitment agency. She was further inspired by a NICE external body internship and attending a technology appraisal committee which led her to York University.

Her dissertation is entitled, Exploring the Scope for Introducing the use of Biologic Therapies into Disease Areas Traditionally Managed by Small Molecules. She said, “Curo’s diverse, fast paced consulting environment is perfect for my summer placement, I’m hoping undertake a systematic review and construct a model to feed the data into and the technology developed here will help me to do that.”

Abi studied Economics with Accountancy (BSc First Class Honours) at the University of East Anglia for her undergraduate, originally planning to train for a career in accountancy. A short stint at an accounting firm revealed it wasn’t going to fulfil her aspirations and she began to explore other options. Looking back at her degree, the wide range of opportunities presented by health economics engaged her interest. After speaking to contacts in the industry, York’s MSc Health Economics course, with its excellent reputation was an obvious choice to continue her studies.

Abi said of her project, Exploring the Options for Linking the Value and Price of New Drugs Outside of Traditional Value-based Pricing, “Pharmaceutical companies are under pressure to prove the value of new drugs and demonstrate improved outcomes. Learning alongside Curo over the coming weeks will provide a great insight into pricing methods in the UK.”

You can keep up to date with their progress on our blog and through updates on LinkedIn and twitter.

Page 1 of 14123456»